Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

Chavez-Macgregor M.; Barlow W.; Pusztai L.; Rastogi P.; Ganz P.; Mamounas E.; Bandos H.; Miao J.; Gralow J.; Hortobagyi G.

首页> 外文期刊>The Breast : >Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

【24h】

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

机译：III期随机，安慰剂对照临床试验评估使用辅助内分泌治疗+/- everolimusin患者的高风险，激素受体（HR）阳性，HER2阴性乳腺癌（BC）：SWOG / NRG / ALLICE S1207（NCT01674140 的）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2019年第1期|共1页
作者
Chavez-Macgregor M.; Barlow W.; Pusztai L.; Rastogi P.; Ganz P.; Mamounas E.; Bandos H.; Miao J.; Gralow J.; Hortobagyi G.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

SWOG Stat Ctr Seattle WA USA;

Yale Univ Canc Ctr New Haven CT USA;

Univ Pittsburgh Pittsburgh PA USA;

UCLA Jonsson Comprehens Canc Ctr Los Angeles CA USA;

Orlando Hlth UF Hlth Canc Ctr Orlando FL USA;

NRG Oncol Pittsburg KS USA;

SWOG Stat Ctr Seattle WA USA;

Univ Washington Seattle Canc Care Alliance Seattle WA 98195 USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140) [J] . Chavez-Macgregor M., Barlow W., Pusztai L., The Breast : . 2019,第期

机译：III期随机，安慰剂对照临床试验评估使用辅助内分泌治疗+/- everolimusin患者的高风险，激素受体（HR）阳性，HER2阴性乳腺癌（BC）：SWOG / NRG / ALLICE S1207（NCT01674140 的）
2. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：NRG肿瘤学的十年结果/ NSABP B-42：延长佐剂内分泌治疗的随机，双盲，安慰剂对照临床试验，延长佐剂内分泌治疗，含有激素受体加乳腺癌（BC）的绝经后妇女用芳香酶抑制剂（AI）完成了先前的佐剂治疗
3. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer-CALGB 40302 (Alliance) [J] . Burstein Harold J., Cirrincione Constance T., Barry William T., Journal of Clinical Oncology . 2014,第35期

机译：内分泌疗法对表皮生长因子受体和人表皮生长因子受体的抑制或不抑制：接受或不接受拉帕替尼的夫伐他汀的随机，双盲，安慰剂对照III期临床试验，用于绝经后激素受体阳性的晚期乳腺癌女性CALGB 40302（联盟）
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized Double-Blind Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) [O] . Harold J. Burstein, Constance T. Cirrincione, William T. Barry, -1

机译：有或没有抑制表皮生长因子受体和人表皮生长因子受体的内分泌治疗2：接受或不接受拉帕替尼的氟维沙坦的随机双盲安慰剂对照的Ⅲ期临床试验用于绝经后激素受体阳性的晚期乳腺癌女性。 CALGB 40302（联盟）
7. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer [O] . Regan, Meredith M., Price, Karen N., Giobbie-Hurder, Anita, 2017

机译：解释乳腺国际组织（BIG）1-98：一项随机，双盲，III期试验，比较来曲唑和他莫昔芬作为辅助内分泌治疗对绝经后激素受体阳性早期乳腺癌患者的影响

Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- everolimusin patients with high-risk, hormone receptor (HR) positive, HER2-negative breast cancer (BC): SWOG/NRG/Alliance S1207 (NCT01674140)

著录项

相似文献

相关主题

期刊订阅